Physician profile
Jay M Berman
NPI 1710924238
$217,942.14
in general payments reported to CMS, 2019-2025
39 companies · $8,322 in 2025
The $8,322 reported for 2025 was more than what 95% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $9,430 · 2021: $42K · 2022: $27K · 2023: $46K · 2024: $19K · 2025: $8,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,619 · Food and Beverage: $4,938 · Travel and Lodging: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,053.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,618.82 |
| Food and Beverage | $4,938.38 |
| Travel and Lodging | $2,701.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $71,412.41 | 2019-2025 | Acessa Provu System |
| Hologic Sales and Service, LLC | $36,193.54 | 2020-2025 | Acessa Provu System, None, Myosure Tissue Removal Device |
| Abbvie INC. | $29,037.86 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Lupin INC. | $26,873.70 | 2019-2020 | |
| Gynesonics, INC. | $16,876.32 | 2021-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $8,583.41 | 2022-2025 | Nexplanon, Nuvaring |
| Merck Sharp & Dohme LLC | $7,064.06 | 2019-2021 | |
| Covidien Lp | $5,998.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,928.15 | 2019-2025 | |
| Myovant Sciences INC. | $4,144.99 | 2021-2022 | |
| Pfizer INC. | $2,607.16 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $1,846.79 | 2023-2025 | Myfembree |
| Amgen INC. | $609.14 | 2019-2022 | |
| Aspira Women'S Health INC | $362.65 | 2020-2022 | |
| Lilly USA, LLC | $277.57 | 2024-2025 | Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $241.58 | 2023-2024 | Veozah |
| Medtronic, INC. | $180.79 | 2025 | Truclear |
| Medical Device Business Services, INC. | $119.46 | 2024 | Stratafix |
| Intuitive Surgical, INC. | $99.36 | 2020 | |
| Coopersurgical, INC. | $92.33 | 2020-2025 | Paragard T 380a |
| Coloplast Corp | $45.07 | 2024 | |
| Mayne Pharma Commercial LLC | $33.69 | 2025 | |
| Itamar Medical INC | $27.82 | 2023 | Watchpatone |
| Sage Therapeutics, LLC | $24.32 | 2024 | |
| Cytyc Surgical Products, LLC | $23.78 | 2025 | Myosure Tissue Removal Device, Novasure |
| Meditrina | $22.58 | 2022 | |
| Boston Scientific Corporation | $21.39 | 2024 | |
| Exact Sciences Corporation | $20.50 | 2024 | Cologuard Collection Kit |
| Minerva Surgical, INC | $19.31 | 2024 | |
| Novo Nordisk INC | $19.05 | 2023 | Wegovy |
| Shield Therapeutics INC | $18.69 | 2024 | |
| Channel Medsystems, INC. | $18.53 | 2023 | |
| Sequel Med Tech, LLC | $18.15 | 2025 | Twiist |
| Gilead Sciences, INC. | $17.73 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.83 | 2025 | Lifevest |
| Medicem INC. | $15.98 | 2024 | |
| Daiichi Sankyo INC. | $14.61 | 2019 | |
| Allergan, INC. | $14.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,600.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.